Strategies involving ICIs, such as PD-L1 antibody-based therapy, are evidently effective in treating various cancers; thus, it is now widely used clinically.5 However, the response rate is limited (approximately 10%–30%), with a need for improvement. The gene discussed is CD274; the disease is cancer.